Dupixent Lawsuit Dupixent lawsuits are being investigated for patients who developed rare blood cancers such as cutaneous T-cell lymphoma (CTCL) after receiving injections, alleging that Sanofi and Regeneron failed to warn about the potential risks of immune suppression and delayed cancer diagnosis.
Tabletop Fire Pit Lawsuit Individuals who suffered severe burns, or families who lost a loved one in a tabletop fire pit explosion, may be eligible for financial compensation through a fire pit injury lawsuit.
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Gilead HIV Drug Class Action Lawsuit Alleges Drug Maker Inflated Prices Through Illegal Scheme That Withheld Safer Treatments January 27, 2020 Irvin Jackson Add Your Comments A healthcare insurance company has filed a lawsuit alleging Gilead worked with other drug companies to illegally manipulate the HIV drug market, resulting in inflated prices and the withholding of safer versions of its drugs, as part of scheme to maximize profits and delay generic competition. MSP Recovery Claims (MSPRC) filed a complaint (PDF) in the U.S. District Court for the Southern District of Florida on January 15, indicating that Gilead and other companies engaged in a plant to suppress competition for its HIV drugs, including Truvada, Viread, Atripla, Complera and Stribild, which resulted in patients, and thus health insurers, paying high prices for drugs that were unnecessarily toxic. In addition to Gilead Sciences, Inc., the lawsuit names Bristol-Myers Squibb, Japan Tobacco, Inc., Akros Pharma, Inc, Johnson & Johnson, and its Janssen R&D Ireland subsidiary as defendants, seeking class action status on behalf of MSPRC and other similarly situated healthcare insurance companies who have paid inflated prices due to the scheme. HIV DRUGS LAWSUITS Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs? Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION HIV DRUGS LAWSUITS Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs? Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION “Through an array of anticompetitive practices—including horizontal agreements constituting per se violations of the antitrust laws, Gilead acquired and maintained a monopoly for drugs that comprise the modern HIV treatment regimen known as ‘combination antiretroviral therapy’ (‘cART’),” the lawsuit states. “The scheme enabled Gilead and its co-conspirators to unlawfully extend patent protection for their drugs, impair entry by generic competitors, and charge exorbitant, supra-competitive prices for the drugs that people living with HIV need to survive.” The HIV drug lawsuit notes Gilead and the other defendants constructed a web of joint development agreements, preventing each co-conspirator from competing against Gilead’s tenofovir disoproxil (TDF) based drugs. This also included allowing them to combine some of their HIV drugs with Gilead drugs, specifically the booster drug Cobicistat, in order to enjoy the latter’s much longer patent protection period. These fixed-dose-combination (FDC) drugs allowed all of the companies involved to continue to sell their drugs at inflated prices without fear of generic competition for an extended period of time. In addition, the lawsuit claims Gilead has known for years that a less toxic version of the drugs could be developed, involving the antiviral tenofovir alafenamide fumarate (TAF). However, the drug maker allegedly placed its desire to increase profits ahead of consumer safety, and withheld the safer alternative for years, until the patent protections expired on TDF drugs and generic equivalents were introduced that would have cut into sales. “Gilead forced patients into treatment with TAF-based FDCs by intentionally degrading some of its key products. Before it sought FDA approval of Stribild, its TDF-based FDC, Gilead knew that it contained a much higher dosage of TDF than necessary, subjecting patients to increased risk of significant adverse side effects,” the lawsuit states. “But Gilead already planned to replace that product with a TAF-based version. Refusing to reduce the dosage in the TDF version artificially magnified the safety differences between it and the TAF-based version, helping Gilead to drive patients to the TAF version and its much longer No-Generics Restraint.” The company did not begin to sell TAF-designed drugs until 2015, which extended Gilead’s essential monopoly on HIV treatments until 2032. TDF drug patents began expiring last year. While generic versions have been introduced, Gilead now markets TAF drugs as a safer and superior alternative, preserving the profits generated from the brand-name medications. The lawsuit joins a growing number of individual complaints filed by plaintiffs nationwide, who say they suffered side effects from Gilead HIV drugs, which all contain TDF, which is toxic to the kidneys and bones, resulting in acute kidney injuries, chronic kidney disease, kidney failure, bone fractures, dental injuries and other complications associated with bone density loss. All of the complaints raise similar allegations that consumers and the medical community have not been adequately warned about the potentially toxic side effects of TDF drugs used for treatment of HIV. Written by: Irvin Jackson Senior Legal Journalist & Contributing Editor Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends. Tags: Atripla, Bone Fracture, Class Action Lawsuit, Complera, Fraud, Gilead, HIV, HIV Drugs, Kidney Damage, Stribild, Truvada, Viread More HIV Drugs Lawsuit Stories Side Effects of Truvada, Other NRTI Drugs Used To Treat HIV Could Cause Glaucoma: Study July 24, 2025 Gilead Settles HIV Drug Lawsuit Over Patent on Truvada and Descovy January 20, 2025 U.S. Government Files Appeal Over Gilead Truvada, Descovy HIV Drug Patents July 10, 2024 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCompanyThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: today) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025) Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: yesterday) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025) Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 2 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)
Side Effects of Truvada, Other NRTI Drugs Used To Treat HIV Could Cause Glaucoma: Study July 24, 2025
Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: today) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025)
Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: yesterday) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)
Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 2 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)